This segment operates 4,192 retail stores, with a growing omnichannel and online presence. Our principal retail brands are Boots in the UK, Thailand, and the Republic of Ireland, Boots Opticians, Benavides in Mexico and Ahumada in Chile. We also have Boots franchise operations in the Middle East and Indonesia.
|Country||Number of retail stores|
|Republic of Ireland||89|
Our retail stores are conveniently located and put pharmacists at the heart of healthcare. About 86% of the UK population lives within ten minutes of a Boots store. Our pharmacists are well-positioned to provide a significant role in the provision of healthcare services, working closely with other primary healthcare providers in the communities we serve.
In addition, Boots UK is one of the leaders in the optical market, with 550 practices, of which 165 operate on a franchise basis. Approximately 30 percent of practices are located in Boots stores with the balance being standalone optical practices.
We continually seek to enhance the position of Boots as a trusted pharmacy brand and a leading provider of healthcare, beauty advice and services in local communities. We do this by delivering expert customer care, through investment in existing stores, by selectively expanding our store portfolio and, increasingly, through developing our omnichannel offering.
The Boots.com website and integrated mobile app allows customers to order from a range of over 33,000 products and collect from approximately 98 percent of the UK’s retail stores the following day. The Boots Advantage Card loyalty program continues to be a key element of the Boots offering, with approximately 11 million active members as of Aug. 31, 2020, in the UK and Ireland.
In addition to Boots stores in the UK, Thailand and the Republic of Ireland, WBA works with franchise partners in the Middle East and Indonesia to bring the iconic Boots brand to new geographies, including United Arab Emirates, Saudi Arabia, Bahrain, Oman and Qatar.
On November 1, 2020, the company and McKesson Corporation closed a transaction to form a combined pharmaceutical wholesale business in Germany, as part of a strategic alliance. The Company owns a 70 percent controlling equity interest in the combined business, which is aimed at advancing patient-centric solutions by enhancing the ability to compete and deliver high customer satisfaction through new services and operational excellence.